Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

use of lanadelumab in patients with acquired angioedema

Inclusion Criteria:

• A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance)
• historical attack rate of >= on attack per month prior to starting tranexamic acid (TAA)

Exclusion Criteria:

• History of anaphylaxis or hypersensitivity to biologics
• History of major systemic disease not well controlled in opinion of the PI
• Women who are pregnant or breast feeding
• Concurrent participation in other clinical trials
• HAE Type 1 or 2 and normal complement HAE